{"title":"Assessment of Cognitive Impairment in Rheumatoid Arthritis.","authors":"Olfa Saidane, Khaoula Zouaoui, Selma Bouden, Leila Rouached, Rawdha Tekaya, Ines Mahmoud, Aicha Ben Tekaya, Leila Abdelmoula","doi":"10.31138/mjr.290724.sah","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objectives of our study were to assess the prevalence of cognitive impairment in Rheumatoid arthritis (RA) and to identify its predictive factors.</p><p><strong>Methods: </strong>A 6-month cross-sectional case-control study englobing patients with RA was carried out. The cognitive evaluation was performed using the Mini Mental State Examination (MMSE), the frontal efficiency battery, the 5-word test, the clock drawing test and the Trail Making Test part-A (TMT-A). Linear regression analyses were conducted to identify predictors of cognitive impairment.</p><p><strong>Results: </strong>We included 35 RA patients and 35 controls. Concerning the RA group, the mean duration of the disease was 12.3 years [1-29 years]. RA was immunopositive in 80% of cases and erosive in 83% of cases. The global cognitive dysfunction assessed by MMSE score was 49%. Depending on the test used, the prevalence of cognitive impairment in RA ranged from 34% to 54%. RA patients presented poorer results regarding the TMT-A than the controls (p = 0.03). The other cognitive tests were comparable between the 2 groups. The main predictive independent factors of cognitive impairment among RA patients were advanced age (p = 0.002), rural environment (p = 0.007), low income (p = 0.01), recent course of RA (p = 0.006), low disease activity (p = 0.002) and low blood sugar (p = 0.003).</p><p><strong>Conclusion: </strong>Global cognitive impairment in RA concerned 49% of our patients. Early identification of the factors associated with this cognitive dysfunction is necessary in order to improve the quality of life of patients.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 2","pages":"236-241"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312458/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.290724.sah","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The objectives of our study were to assess the prevalence of cognitive impairment in Rheumatoid arthritis (RA) and to identify its predictive factors.
Methods: A 6-month cross-sectional case-control study englobing patients with RA was carried out. The cognitive evaluation was performed using the Mini Mental State Examination (MMSE), the frontal efficiency battery, the 5-word test, the clock drawing test and the Trail Making Test part-A (TMT-A). Linear regression analyses were conducted to identify predictors of cognitive impairment.
Results: We included 35 RA patients and 35 controls. Concerning the RA group, the mean duration of the disease was 12.3 years [1-29 years]. RA was immunopositive in 80% of cases and erosive in 83% of cases. The global cognitive dysfunction assessed by MMSE score was 49%. Depending on the test used, the prevalence of cognitive impairment in RA ranged from 34% to 54%. RA patients presented poorer results regarding the TMT-A than the controls (p = 0.03). The other cognitive tests were comparable between the 2 groups. The main predictive independent factors of cognitive impairment among RA patients were advanced age (p = 0.002), rural environment (p = 0.007), low income (p = 0.01), recent course of RA (p = 0.006), low disease activity (p = 0.002) and low blood sugar (p = 0.003).
Conclusion: Global cognitive impairment in RA concerned 49% of our patients. Early identification of the factors associated with this cognitive dysfunction is necessary in order to improve the quality of life of patients.